ALT5 Sigma (NASDAQ:AIFC) Posts Earnings Results

ALT5 Sigma (NASDAQ:AIFC) issued its quarterly earnings results on Monday. The company reported $0.42 EPS for the quarter, Zacks reports. ALT5 Sigma had a negative return on equity of 68.25% and a negative net margin of 2,483.94%.

ALT5 Sigma Stock Performance

Shares of NASDAQ:AIFC traded up $0.02 during midday trading on Monday, hitting $0.42. The company had a trading volume of 1,085,555 shares, compared to its average volume of 2,509,993. ALT5 Sigma has a twelve month low of $0.36 and a twelve month high of $8.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.82 and a quick ratio of 0.82. The business’s 50-day simple moving average is $0.54 and its 200-day simple moving average is $0.98.

Hedge Funds Weigh In On ALT5 Sigma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its holdings in shares of ALT5 Sigma by 42.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 52,632 shares of the company’s stock worth $58,000 after acquiring an additional 15,731 shares during the period. SIH Partners LLLP purchased a new stake in shares of ALT5 Sigma in the third quarter valued at about $54,000. Raymond James Financial Inc. grew its holdings in shares of ALT5 Sigma by 39,884.0% in the third quarter. Raymond James Financial Inc. now owns 19,992 shares of the company’s stock valued at $54,000 after purchasing an additional 19,942 shares during the period. Shay Capital LLC acquired a new stake in ALT5 Sigma during the third quarter worth about $133,000. Finally, Private Advisor Group LLC acquired a new stake in ALT5 Sigma during the third quarter worth about $61,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALT5 Sigma in a research note on Tuesday, July 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.